Condition: High-risk Plasma Cell Neoplasms · Sponsor: Affiliated Hospital to Academy of Military Medical Sciences
This is a single arm study to evaluate the safety and efficacy of CAR BCMA-CD70 CAR-T cell therapy for high-risk plasma cell neoplasms.
This description comes directly from the study's public registry record.
Yamei Wu · +86 01066947164 · rippleya@126.com
Always discuss trial participation with your own doctor first.
| the Fifth Medical Center of Chinese People's Liberation Army General Hospital | Beijing, Beijing Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07416682